- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | PSYENCE BIOMEDICAL LTD. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 25.06. | PSYENCE BIOMEDICAL LTD. - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
| PSYENCE BIOMEDICAL Aktie jetzt für 0€ handeln | |||||
| 25.06. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 18.06. | Psyence Biomedical Ltd.: Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025 | 286 | Newsfile | Denver, Colorado--(Newsfile Corp. - June 18, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced that Psychedelic Science 2025 ("PS2025") - the world's... ► Artikel lesen | |
| 17.06. | Psyence BioMed regains Nasdaq compliance following reverse stock split | 1 | Seeking Alpha | ||
| 17.06. | Psyence Biomedical regains Nasdaq compliance after reverse split | 4 | Investing.com | ||
| 17.06. | Psyence Biomedical Ltd.: Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing Requirements | 205 | Newsfile | New York, New York--(Newsfile Corp. - June 17, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced that it has received formal notification from the Nasdaq... ► Artikel lesen | |
| 11.06. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 27.05. | Psyence BioMed advances Phase IIb psilocybin trial with new CRO partnershi | 2 | Investing.com | ||
| 27.05. | Psyence Biomedical Ltd.: Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial | 308 | Newsfile | New York, New York--(Newsfile Corp. - May 27, 2025) - Psyence BioMed (NASDAQ: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company developing nature-derived psilocybin therapies for... ► Artikel lesen | |
| 20.05. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 06.05. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 01.05. | Psyence Biomedical to execute 1-for-7.97 reverse stock split | 5 | Seeking Alpha | ||
| 01.05. | Psyence Biomedical kündigt Aktienzusammenlegung an | 6 | Investing.com Deutsch | ||
| 01.05. | Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split | 268 | Newsfile | New York, New York--(Newsfile Corp. - May 1, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced the effective date of its 1-for-7.97 share consolidation... ► Artikel lesen | |
| 23.04. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 18.04. | Psyence BioMed gets Nasdaq notice for non-compliance | 1 | Seeking Alpha | ||
| 18.04. | Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency | 442 | Newsfile | New York, New York--(Newsfile Corp. - April 17, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") announced today that it received a notification letter dated April... ► Artikel lesen | |
| 15.04. | Psyence BioMed erhöht Beteiligung an PsyLabs mit 500.000 US-Dollar Investition | 2 | Investing.com Deutsch | ||
| 15.04. | Psyence BioMed boosts stake in PsyLabs with $500k investment | 2 | Investing.com |
1 2 3 Weiter >>
51 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOLINERX | 3,283 | -100,00 % | BioLineRx Ltd: BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting | - 4 of 11 PDAC patients in the pilot phase remained progression free at over one year
- Poster presentation on Saturday, May 31 st
TEL AVIV, Israel, May 30, 2025... ► Artikel lesen | |
| TRANSCODE THERAPEUTICS | 11,010 | 0,00 % | TransCode Therapeutics, Inc.: TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported | 15 patients treated across four escalating dose levels of TTX-MC138
No significant safety or dose limiting toxicities reported
10 patients remain on study with... ► Artikel lesen | |
| SILEXION THERAPEUTICS | 0,851 | 0,00 % | Silexion Therapeutics Corp: Silexion Therapeutics Announces 1-for-15 Reverse Share Split | Grand Cayman, Cayman Islands, July 16, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference... ► Artikel lesen | |
| MINK THERAPEUTICS | 17,600 | +6,67 % | XFRA 6Q40: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| EVOTEC | 7,100 | +4,23 % | EQS-Adhoc: Evotec SE: Evotec passt Umsatzprognose an und bestätigt Gewinnprognose | EQS-Ad-hoc: Evotec SE / Schlagwort(e): Prognoseänderung
Evotec SE passt Umsatzprognose an und bestätigt Gewinnprognose
21.07.2025 / 11:25 CET/CEST
Veröffentlichung einer Insiderinformation... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,255 | 0,00 % | Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses? | ||
| IMMUNOVANT | 18,320 | 0,00 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 | Immunovant's new management team is focused on rapid clinical execution for the six announced indications for IMVT-1402, including a second potentially registrational study in Graves' disease (GD)... ► Artikel lesen | |
| QIAGEN | 43,500 | +1,80 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 48 auf 50 Euro angehoben und die Einstufung auf "Buy" belassen. Analyst Harry Gillis "diagnostiziert" eine defensive... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 14,630 | 0,00 % | Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies | - New open label data in Becker demonstrated sustained disease stabilization up to three years, reinforcing prior clinical findings -- Ongoing pivotal trial and FDA Type C meeting provide... ► Artikel lesen | |
| JANUX THERAPEUTICS | 25,970 | 0,00 % | Raymond James startet Coverage für Janux Therapeutics mit "Outperform"-Rating | ||
| VERVE THERAPEUTICS | 11,130 | 0,00 % | Lilly completes tender offer for Verve Therapeutics shares | ||
| VIR BIOTECHNOLOGY | 5,760 | 0,00 % | Vir Biotechnology, Inc. - 8-K, Current Report | ||
| SANA BIOTECHNOLOGY | 5,125 | 0,00 % | Citi Maintained a Buy Rating on Sana Biotechnology (SANA) | ||
| BEAM THERAPEUTICS | 20,960 | 0,00 % | Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 27,545 | 0,00 % | Summit Therapeutics vor Mega-Deal: Aktie +15% | Papiere von Summit Therapeutics legen heute in der Spitze um +15% zu. Vorausgegangen ist ein Bloomberg-Bericht um einen bevorstehenden Mega-Deals mit dem Pharmakonzern AstraZeneca. Laut Bloomberg News... ► Artikel lesen |
Das Unternehmen PSYENCE BIOMEDICAL LTD kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 9,580 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PSYENCE BIOMEDICAL LTD finden Sie auf Wallstreet Online.